Fluorescence before and after robotic addition of GLP-1 was serially read using a Flexstation 3 with 485 nm excitation, 525 nm emission (cut-off 515 nm), and expressed relative to average baseline to establish fold change, with GLP-1 concentration response data analyzed by four-parameter fit
Our Team Meet Your Care Team Duke Keller Medical Director Oscar Veloria Provider Christopher Dangerfield, PA-C Provider Nahiyan Hasan Clinical Staff Shannon Walsh Clinical Staff Wendy Luzanilla Office Staff Questions
Renal Fibrosis and Chronic Kidney Disease Renal fibrosis is a major driver of progressive kidney function loss in CKD
Hypoglycemia symptoms can include shakiness, sweating, fast heartbeat, hunger, dizziness, confusion, or weakness
When used properly, GLP-1 therapy can help reduce hunger, improve satiety, support better eating patterns, and make sustainable weight loss more achievable